Ploos van Amstel Sophie, Vogelzang Judith L, Starink Marcus V, Jager Kitty J, Groothoff Jaap W
Department of Paediatric Nephrology, Emma Children's Hospital and.
Department of Paediatric Nephrology, Emma Children's Hospital and
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2198-204. doi: 10.2215/CJN.03630415. Epub 2015 Oct 1.
ESRD is associated with an increased risk of malignancies. We analyzed the incidence of cancer in patients with pediatric ESRD after long-term follow-up.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All Dutch patients born before 1979 who were transplanted at age <15 years old in 1972-1992 were followed until 2010. We explored type and incidence of malignancies in patients compared with the general population using the National Cancer Registry.
After a median of 25.3 years (1.3-37.8) of transplantation and at a median age of 33.5 years old (11.0-49.0), 105 primary malignancies had occurred in 54 of 249 patients. Among them, cutaneous squamous cell carcinoma was most frequent. Patients ages 25-30 years old had developed 16.5 times (95% confidence interval, 7.9 to 34.6) as many de novo tumors and 991 times (95% confidence interval, 313 to 3137) as many de novo cutaneous squamous cell carcinomas as their general population counterparts; in survivors ages 45-50 years old, these numbers were 81.5 (95% confidence interval, 50.7 to 131.1) and 2610 (95% confidence interval, 1596 to 4267), respectively. Cumulative incidence competing risk analysis showed that, after 30 years of transplantation, 41% of the survivors had developed cancer; 31% had developed a second de novo cancer <1 year after initial cancer diagnosis.
Cancer is highly prevalent among patients with pediatric ESRD after 25.3 years of transplantation, with a high rate of recurrence.
终末期肾病(ESRD)与恶性肿瘤风险增加相关。我们对长期随访后的小儿ESRD患者的癌症发病率进行了分析。
设计、地点、参与者及测量方法:对1979年以前出生、于1972年至1992年期间在15岁之前接受移植的所有荷兰患者进行随访,直至2010年。我们使用国家癌症登记处的数据,探讨了这些患者与普通人群相比的恶性肿瘤类型和发病率。
在移植后中位时间25.3年(1.3至37.8年)、中位年龄33.5岁(11.0至49.0岁)时,249例患者中的54例发生了105例原发性恶性肿瘤。其中,皮肤鳞状细胞癌最为常见。25至30岁的患者发生的新发肿瘤是普通人群的16.5倍(95%置信区间,7.9至34.6),新发皮肤鳞状细胞癌是普通人群的991倍(95%置信区间,313至3137);在45至50岁的幸存者中,这些数字分别为81.5(95%置信区间,50.7至131.1)和2610(95%置信区间,1596至4267)。累积发病率竞争风险分析表明,移植30年后,41%的幸存者患了癌症;31%的患者在初次癌症诊断后不到1年又患了第二种新发癌症。
小儿ESRD患者在移植25.3年后癌症高发,且复发率高。